|
|
|
| Clinical Application and Evaluation of Pharmacogenomics in Tumor Chemotherapy |
| Feng Jifeng |
| Department of Internal Medicine, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu. 210009, China |
|
|
|
|
Abstract In the treatment of tumor patients, how to select the chemotherapy regimen with better efficacy, less toxicity and expense is a difficult problem that perplexes clinical doctors for a long time. Pharmacogenetics is to study the influence of genetic factors on pharmacokinetics, whereas pharmacogenomics is to study the relationship between various gene mutations and drug efficacy and safety. With molecular biology developing, pharmacogenetics and pharmacogenomics are considered to be essential in the reduction of adverse reactions, improvement of efficacy and realization of individualized treatment. In this article, the clinical application and evaluation of pharmacogenomics in tumor chemotherapy were primarily investigated.
|
|
|
|
|
|
1 Zhu H, Deng FY, Mo XB, et al. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics 2014; 15: 551-66.
2 Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: The University of Maryland personalized anti-plateletpharmacogenetics program. Am J Med Genet C Semin Med Genet 2014; 166: 76-84.
3 Fushiya N, Takagi I, Nishino H, et al. Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Anticancer Drugs 2013; 24: 617-22.
4 Liu Y, Xia Q, Jia Y, et al. Significance of differential expression of thymidylate synthase in normal and primary tumor tissues from patients with colorectal cancer. J Hematol Oncol 2011; 4: 33.
5 Wang Z, Chen JQ, Liu JL, et al. Polymorphisms inERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol 2012; 12: 137.
6 Lu JW, Gao CM, Wu JZ, et al. Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Cancer 2004; 23: 958-62.
7 Zhou C, Ren S, Zhou S, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 2010; 40: 954-60.
8 Liu L1, Yuan P, Wu C, et al. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced nonsmall-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 2011; 73: 110-5.
9 Cheng L, Li M, Hu J, et al. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 2014; 73: 551-60.
10 Goetz MP, McKean HA, Reid JM, et al. UGT1A1 genotypeguided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs 2013; 31: 1559-67.
11 Karakosta M, Kalotychou V, Kostakis A, et al. UGT1A1*28 Polymorphism in Chronic Lymphocytic Leukemia: The First Investigation of thePolymorphism in Disease Susceptibility and Its Specific Cytogenetic Abnormalities. Acta Haematol 2014; 132: 59-67.
12 Gao J, Zhou J, Li Y, et al. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea inChinese colorectal cancer patients. Med Oncol 2013; 30: 604.
13 Gong W, Zhang X, Wu J, et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012; 75: 374-80.
14 Kaplan M, Mahon SM. Response to “Understanding CYP2D6 and its role in tamoxifen metabolism”. Oncol Nurs Forum 2014; 41: 12.
15 Chamnanphon M, Pechatanan K, Sirachainan E, et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med 2013; 6: 37-48. |
| [1] |
TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91. |
| [2] |
Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62. |
| [3] |
QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66. |
| [4] |
MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70. |
| [5] |
LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85. |
| [6] |
WANG Peng. Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside[J]. Journal of International Translational Medicine, 2017, 5(2): 92-97. |
|
|
|
|
